cd14 microbeads miltenyi biotec (Miltenyi Biotec)
Structured Review
Cd14 Microbeads Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/10__1016_slash_j__isci__2026__116736-639-174-176
Average 94 stars, based on 23 article reviews
Images
Related Articles
Purification:Article Title: PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy Article Snippet: .. Magnetic Cell Separation:Article Title: PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy Article Snippet: .. Isolation:Article Title: PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy Article Snippet: .. Article Title: Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation Article Snippet: NK cells were isolated from freshly isolated PBMCs using the NK-cell enrichment kit (Stem Cell Technologies) ( 70 ). .. Purity of isolated NK cells (95–99% CD3 − CD56 + ) was determined by flow cytometry using PerCP/Cy5.5-conjugated anti-CD3 (Biolegend) and PC7-conjugated anti-CD56 (Beckman Coulter) antibodies. mDCs were isolated from the same PBMCs as NK cells using the Article Title: Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma Article Snippet: First, CD14 + and CD19 + cells were depleted with the CliniMACS CD14 and CD19 reagents followed by a positive selection of CD1c (BDCA-1) + myDC and CD141 (BDCA-3) + myDC by using CliniMACS CD1c (BDCA-1)-biotin microbeads, CliniMACS CD141 (BDCA-3)-biotin microbeads and CliniMACS Anti-Biotin Reagent (Miltenyi) using the CliniMACS Prodigy platform (Miltenyi Biotec, Bergisch Gladbach, Germany). .. The isolated Article Title: Human dendritic cells activated with MV130 induce Th1, Th17 and IL‐10 responses via RIPK2 and MyD88 signalling pathways Article Snippet: .. Naïve CD4 + T cells, total DC fraction, enriched fractions of mDCs and pDCs were isolated with “Naïve CD4 + T Cell”, “Blood DCs II”, Selection:Article Title: Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells Article Snippet: .. Briefly, patients underwent a leukapheresis and next, CD14 + and CD19 + cells were depleted using CliniMACS ® CD14 reagent and CliniMACS ® CD19 reagent, followed by positive selection of Flow Cytometry:Article Title: Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation Article Snippet: NK cells were isolated from freshly isolated PBMCs using the NK-cell enrichment kit (Stem Cell Technologies) ( 70 ). .. Purity of isolated NK cells (95–99% CD3 − CD56 + ) was determined by flow cytometry using PerCP/Cy5.5-conjugated anti-CD3 (Biolegend) and PC7-conjugated anti-CD56 (Beckman Coulter) antibodies. mDCs were isolated from the same PBMCs as NK cells using the Staining:Article Title: HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa. Article Snippet: Background: The Human T-cell Leukemia Virus type 1 (HTLV-1) is the causative agent of several inflammatory diseases, including HTLV-1-associated inflammatory myopathies (HAIM).. Little is known about the virological and immunological characteristics of this viral disease.. Objectives: To characterize the histological and virological features of HAIM patients, in order to better understand the pathogenetic mechanisms and unravel new biological markers of this disease. Ubiquitin Proteomics:Article Title: HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa. Article Snippet: Background: The Human T-cell Leukemia Virus type 1 (HTLV-1) is the causative agent of several inflammatory diseases, including HTLV-1-associated inflammatory myopathies (HAIM).. Little is known about the virological and immunological characteristics of this viral disease.. Objectives: To characterize the histological and virological features of HAIM patients, in order to better understand the pathogenetic mechanisms and unravel new biological markers of this disease. Centrifugation:Article Title: Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma Article Snippet: First, CD14 + and CD19 + cells were depleted with the CliniMACS CD14 and CD19 reagents followed by a positive selection of CD1c (BDCA-1) + myDC and CD141 (BDCA-3) + myDC by using CliniMACS CD1c (BDCA-1)-biotin microbeads, CliniMACS CD141 (BDCA-3)-biotin microbeads and CliniMACS Anti-Biotin Reagent (Miltenyi) using the CliniMACS Prodigy platform (Miltenyi Biotec, Bergisch Gladbach, Germany). .. The isolated Saline:Article Title: Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma Article Snippet: First, CD14 + and CD19 + cells were depleted with the CliniMACS CD14 and CD19 reagents followed by a positive selection of CD1c (BDCA-1) + myDC and CD141 (BDCA-3) + myDC by using CliniMACS CD1c (BDCA-1)-biotin microbeads, CliniMACS CD141 (BDCA-3)-biotin microbeads and CliniMACS Anti-Biotin Reagent (Miltenyi) using the CliniMACS Prodigy platform (Miltenyi Biotec, Bergisch Gladbach, Germany). .. The isolated Suspension:Article Title: Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma Article Snippet: First, CD14 + and CD19 + cells were depleted with the CliniMACS CD14 and CD19 reagents followed by a positive selection of CD1c (BDCA-1) + myDC and CD141 (BDCA-3) + myDC by using CliniMACS CD1c (BDCA-1)-biotin microbeads, CliniMACS CD141 (BDCA-3)-biotin microbeads and CliniMACS Anti-Biotin Reagent (Miltenyi) using the CliniMACS Prodigy platform (Miltenyi Biotec, Bergisch Gladbach, Germany). .. The isolated |


